Jaydess

Levonorgestrel, the active ingredient in Jaydess, is a progestin presented as a 13.5 mg intrauterine system (IUS) for intrauterine use. It provides long‑acting hormonal contraception by releasing levonorgestrel directly into the uterine cavity, preventing pregnancy in women of reproductive age.

GNH USA supplies Jaydess as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards. The company ensures product quality, traceability and compliance with global pharmacovigilance requirements.

Jaydess, a levonorgestrel‑based intrauterine system, is indicated for hormonal contraception.

- Contraception (prevention of pregnancy): provides continuous birth control for up to three years. - Long‑acting reversible contraception (LARC): offers a hormone‑based method that does not require daily dosing. - Women desiring a low‑maintenance contraceptive: delivers levonorgestrel locally, reducing systemic exposure.

Common Side Effects: - Irregular vaginal bleeding: spotting or breakthrough bleeding, especially during the first months. - Amenorrhea: absence of menstrual periods after initial adjustment. - Pelvic or cramping pain: mild discomfort around the insertion site. - Breast tenderness: mild swelling or sensitivity. - Acne or oily skin: hormonal changes may affect skin condition.

Serious or Rare Side Effects: - Uterine perforation: rare injury to the uterine wall during insertion. - Device expulsion: the IUS may be partially or fully expelled. - Pelvic inflammatory infection: signs include fever, foul discharge, or severe pain. - Ectopic pregnancy: occurs if pregnancy happens despite the device. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hormonal side‑effects: mood changes or severe headache.

Before insertion, clinicians should consider several safety measures.

- Screen for pregnancy: confirm the patient is not pregnant prior to placement. - Assess uterine abnormalities: evaluate for fibroids, congenital anomalies, or scarring. - Monitor for infection: watch for signs of pelvic infection after insertion. - Counsel on bleeding patterns: inform patients about possible irregular bleeding or amenorrhea. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from Jaydess can be affected by other medicines.

Major Interactions (Avoid): - Enzyme inducers (e.g., rifampin, carbamazepine): may lower levonorgestrel levels and reduce efficacy. - Antiretroviral drugs (e.g., efavirenz): can decrease hormonal activity. - St. John's wort: may reduce contraceptive effectiveness. - Certain anticonvulsants (e.g., phenytoin): can accelerate hormone metabolism.

Moderate Interactions (Monitor Closely): - Antibiotics (e.g., griseofulvin): may have a modest impact on hormone levels. - Herbal supplements (e.g., ginkgo biloba): monitor for any changes in bleeding. - Hormonal therapies (e.g., combined oral contraceptives): assess cumulative hormonal exposure.